Two Lines on a Test: What Pregnant AuDHD Australians Face the Moment They Find Out

AUDHD Australia
,

For thousands of Australian women who have finally — after years, sometimes decades — found a medication that lets them think, plan and stay upright in their own lives, a positive pregnancy test can feel like the start of a countdown. Not to birth. To a decision that used to be framed as simple: stop your ADHD medication immediately, and brace for impact.

The science has moved. The old script hasn’t.

New population-based research is reshaping what pregnant AuDHD Australians — and their clinicians — can reasonably be told about medication, while Australia’s first dedicated perinatal resource for autistic people has only just opened its doors. Together, they hint at something many AuDHD women have long suspected: the system has been treating them like a risk to be neutralised, not like patients who deserve modern, evidence-informed care.

The old advice and the new evidence

Prescribing stimulants during pregnancy has never been simple in Australia. Methylphenidate was reclassified by the Therapeutic Goods Administration from Pregnancy Category B3 to Category D in 2021, after large observational studies reported a small increase in foetal cardiac malformations among women exposed in the first trimester. Lisdexamfetamine remains Category B3. Dexamphetamine is not formally categorised in the TGA database, but has historically been managed as a cautious Category B-equivalent. Category D does not mean contraindicated — it means the drug may cause harm and that a clear therapeutic rationale is needed. But “Category D” on a label, combined with a pregnancy test, has meant one thing in most clinical rooms for a long time: stop.

That default is being re-examined. In March 2025, a team led by Kathrine Bang Madsen published a population-based cohort study in Molecular Psychiatry that tracked 861,650 Swedish children born between 2008 and 2017. Of those, 2,257 were exposed to ADHD medication in utero and another 3,917 were born to mothers who discontinued medication before pregnancy. After adjusting for maternal psychiatric history and sociodemographic factors, the researchers reported no increased hazard of any neurodevelopmental disorder in exposed children compared with the discontinuation group — not for ADHD (HR 0.92), not for autism (HR 0.86), not for any neurodevelopmental diagnosis overall (HR 0.95).

A separate systematic review, published in 2025 in Archives of Women’s Mental Health and covering twelve cohort studies assessed as high quality, reached a similar conclusion for most agents. Seven of the twelve found no significant adverse effect on mother or baby. Three flagged associations with pre-eclampsia or gastroschisis that the review described as mixed and needing further investigation. Only modafinil — rarely used for ADHD in Australia — was clearly associated with higher risk of congenital malformations and recommended for cessation before conception.

None of this makes stimulants risk-free. It does mean the risk needs to be weighed against the risks of untreated ADHD in pregnancy — impulsivity, missed appointments, increased accident risk, higher rates of antenatal depression and anxiety, and the cascading consequences of a suddenly-disrupted executive function system during the most cognitively demanding year of many women’s lives.

What Australian data actually shows

The pattern is visible in Australian prescribing data too. A 2025 systematic review by Dani Russell, Erin Kelty and colleagues at the University of Western Australia, published in the Journal of Psychoactive Drugs, found that the prevalence of ADHD medication dispensing during pregnancy varied enormously across studies — from 0.07 to 6.01 per 1,000 pregnancies — with methylphenidate the most commonly prescribed agent. Western Australia’s own retrospective cohort, also led by the UWA team and published in Archives of Women’s Mental Health, compared women who continued dexamphetamine in pregnancy with women who ceased. The continuers did not show a consistent safety signal against them. Women who ceased had greater odds of threatened abortion. The unexposed comparison group fared best on some outcomes, but that group was also healthier at baseline, and the study’s authors warned against interpreting the findings as a universal recommendation to stop.

The UWA group has argued publicly that Australian women deserve a more individualised conversation than the one they are often offered — something closer to the thoughtful benefit-versus-risk discussions pregnant women already have with their GPs about antidepressants and anti-epileptics. In March 2024, UWA’s own news service described the default of stopping ADHD medication in pregnancy as a question rather than an answer.

Paracetamol: a related fear, finally put to bed

A second medication anxiety many AuDHD parents-to-be carry deserves its own mention. In January 2026, The Lancet Obstetrics, Gynaecology & Women’s Health published the largest meta-analysis yet on prenatal paracetamol exposure and child neurodevelopment. When the researchers restricted their analysis to sibling-comparison studies — the gold standard for controlling for shared genetics and environment — the association between pregnancy paracetamol use and autism, ADHD or intellectual disability disappeared. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists reaffirmed that paracetamol remains Pregnancy Category A in Australia and should be used at the lowest effective dose for the shortest duration needed.

For AuDHD women who have spent a pregnancy fearing they caused their own child’s neurodivergence with a Panadol, this is a small but important release.

The other half of the story: perinatal care itself

Medication is only one slice of what pregnancy looks like for AuDHD Australians. The other is the hospital, the clinic, the midwife, the postnatal ward — and the sensory, communication and executive-function demands each one imposes.

A 2024 systematic review published in Women and Birth by Jata Elliott, Kate Buchanan and Sara Bayes at Edith Cowan University synthesised eleven studies of autistic and ADHD perinatal experiences. Three themes emerged: how care providers did or did not offer support, how perinatal mental health needs went unmet, and how neurodivergent parents nonetheless found growth and resilience. Across the included studies, the review reported markedly higher rates of perinatal depression and anxiety in neurodivergent mothers — in one underlying study, roughly 16.76 per cent of the ADHD group compared with 3.29 per cent of the non-ADHD group. Autistic women in the included studies reported being more likely to find the sensory environment of labour overwhelming, more likely to experience caesarean section, and less satisfied with postnatal care than non-autistic peers.

The AuDHD double bind runs right through all of this. Autistic sensory sensitivity meets the noise, lighting and touch of a labour ward. ADHD executive-function strain meets the appointment-heavy maze of antenatal care. Masking — the learned habit of presenting as neurotypical — meets the moment a clinician asks “how are you coping?” and the honest answer does not come out.

Australia’s first real attempt to do this differently

The most concrete Australian response so far opened on 25 June 2025, when Autism Spectrum Australia (Aspect) launched its Autistic Pregnancy and Parenthood Hub, co-produced over sixteen months by the Aspect Research Centre for Autism Practice (ARCAP) and funded by the Victorian Government’s Diverse Communities, Mental Health and Wellbeing program. The hub provides evidence-informed information for autistic expectant and new parents, lived-experience stories, strategies for managing medical appointments, sensory-friendly birthing options, and three free training modules for clinicians and midwives who want to offer inclusive care.

It is the first resource of its kind in Australia. It is also a quiet rebuke of how long AuDHD women have been asked to adapt themselves to perinatal care, rather than the other way around.

What this all means for AuDHD Australians, today

The practical implication is not that every pregnant AuDHD woman should keep taking her medication. It is that the decision belongs to her and her prescriber, informed by current evidence rather than by folk wisdom, and weighed against the very real risks of untreated ADHD and autistic burnout in pregnancy and the postpartum year. Pregnancy is one of the highest-demand periods an AuDHD brain will ever face. Treating it as a routine condition to be medicated away — or as a reason to strip away supports — misses the point of both.

Australia still has work to do. The National Autism Strategy 2025–2031 names perinatal care as an area of need but does not yet fund a dedicated perinatal stream. No Australian clinical guideline yet integrates the UWA and Aspect evidence bases with the Australian Evidence-Based Clinical Practice Guideline for ADHD. And in most states, a GP cannot independently restart ADHD medication after a pregnancy pause without specialist involvement — so discontinuation during pregnancy can, in practice, mean discontinuation for much longer, because rebuilding the prescribing chain takes that long.

For the women sitting at home right now, looking at two lines on a stick and wondering what comes next: the science is better than you were told. The care is — slowly — catching up. And the first question to ask your clinician is the one that should always have been on the table. What does the evidence actually say?

Sources

Leave a Reply

Discover more from AUDHD Australia

Subscribe now to keep reading and get access to the full archive.

Continue reading